Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2207-2211

  Suvajdzic, Nada ^a,b   Djurdjevic, Predrag ^c,d   Todorovic, Milena ^a,b   Perunicic, Maja ^a   Roksanda Stojanovic ^b,e   Novkovic, Aleksandra ^f   Mihaljevic, Biljana ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER KRAGUJEVAC   (Serbia)

^d UNIVERSITY OF KRAGUJEVAC   (Serbia)

^e INSTITUTE OF RHEUMATOLOGY   (Serbia)

^f Clinical Hospital Centre Zemun   (Serbia)

Author keywords

Non Hodgkin lymphoma; Rheumatoid arthritis; Sj gren's syndrome; Systemic lupus erythematosus

Indexed keywords

ANTIRHEUMATIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; PREDNISOLONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DERMATOMYOSITIS; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LATENT PERIOD; LUPUS ERYTHEMATOSUS; LYMPHOCYTOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNE DISEASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84872809648     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0022-x     Document Type: Article

References (40)

1. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases. Arch Intern Med. 2005;165:2337-44.
2. Bernatsky S, et al. Non-Hodgkin lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1507-9.
3. Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma. 2008;8:87-93.
4. Smedby KE, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma subtype. J Nat Cancer Inst. 2006;98:51-60.
5. Smedby KE. et.al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029-38.
6. Hansen A, Lipsky PE, Dorner T. B-cell lymphoprolifeartion in chronic inflamatory rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3:561-9.
7. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15:2069-77.
8. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum. 2004;50:1740-51.
9. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of hematopoietic and lymphoid tissue. World Health Organisation Classification of Tumours Lyon: IARC Press; 2001.
10. Kristinsson SY, et al. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Hematologica. 2009;94:1581-9.
11. Arnett FC, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
12. Tan EM, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
13. Vitali C, et al. Preliminary classification criteria for Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36:340-7.
14. Masi D, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-90.
15. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-7.
16. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-7.
17. Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkin lymphomas. Semin Oncol. 1990;17:43-50.
18. Lister T, et al. Report of the committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotsworld meeting. J Clin Oncol. 1989;7:1630-6.
19. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36:842-54.
20. Shipp M, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-94.
21. Solal-Céligny P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-65.
22. Smedby KE, et al. Autoimmune disorders and risk of non Hodgkin's lymphoma subtypes: a pooled analysis within the Interlymph Consortium. Blood. 2008;111:4029-38.
23. Landgren O, Pfeiffer RM, Kristinsson SY, Björkholm M. Survival patterns in patients with Hodgkin's lymphoma with a preexisting hospital discharge diagnosis of autoimmune disease. J Clin Oncol. 2010;28:5081-7.
24. Anderson LA, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125:398-405.
25. Xu Y, Wiernik PH. Systemic lupus erythematosus and B-cell hematological malignancy. Lupus. 2001;10:841-50.
26. Bernatsky S, et al. Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology. 2007;46:830-2.
27. Hoshida Y, et al. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer. 2003;108:443-9.
28. Ekstrom K, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003;48:963-70.
29. Lin AY, Tucker MA (1998) Epidemiology of Hodgkin's disease and Non-Hodgkin's lymphomas. In: Canellos GP, Lister TA, Sklar JR. The lymphomas. 1st ed. Philadelphia: W.B. Saunders Company, pp 43-61.
30. Mikuls TR, et al. Prospective study of survival outcomes in non-Hodgkin's lymphoma patients with rheumatoid arthritis. J Clin Oncol. 2006;24:1597-602.
31. King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheumatol. 2007;26:1491-4.
32. Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate and lymphoma in patients with rheumatoid arthritis and primary Sjo{double acute}gren's syndrome: case series. J Rheumatol. 2001;28:47-53.
33. Theander E, et al. Lymphoma and other malignancies in primary Sjo{double acute}gren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796-803.
34. Baecklund E, et al. Association of chronic inflamation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheumatol. 2006;54:692-701.
35. Engels EA, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphomas: a case-control study. Am J Epidemiol. 2005;162:1153-61.
36. Baecklund E, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum. 2003;48:1543-50.
37. Hellgren K, et al. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis. 2010;69:654-9.
38. Mariette X, et al. Lymphoma in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909-15.
39. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjo{double acute}gren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action of Sjo{double acute}gren's syndrome. Arthritis Rheum. 1999;42:1765-72.
40. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 1997;40:1580-6.